Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b tria...

por Stohl, William, Merrill, Joan T., Looney, R. John, Buyon, Jill, Wallace, Daniel J., Weisman, Michael H., Ginzler, Ellen M., Cooke, Blaire, Holloway, Donna, Kaliyaperumal, Arunan, Kuchimanchi, Kameswara Rao, Cheah, Tsui Chern, Rasmussen, Erik, Ferbas, John, Belouski, Shelley S., Tsuji, Wayne, Zack, Debra J.
Publicado 2015